# PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days

Study · id `cardio:ct-nct03808376` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03808376](<https://clinicaltrials.gov/study/NCT03808376>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03808376

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 208 participants.

## Technical summary

Registry record NCT03808376. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-12-27 (actual); primary completion 2020-05-08 (actual). Results posted on 2024-08-20.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 208 participants (enrolled count; ClinicalTrials.gov record NCT03808376, source copy `cardio:ctgov-nct03808376-2024-08-20`, retrieved 2026-10-26)
- Started: 2018-12-27 (actual) (ClinicalTrials.gov record NCT03808376, source copy `cardio:ctgov-nct03808376-2024-08-20`, retrieved 2026-10-26)
- Primary completion: 2020-05-08 (actual) (ClinicalTrials.gov record NCT03808376, source copy `cardio:ctgov-nct03808376-2024-08-20`, retrieved 2026-10-26)
- Completion: 2020-05-08 (actual) (ClinicalTrials.gov record NCT03808376, source copy `cardio:ctgov-nct03808376-2024-08-20`, retrieved 2026-10-26)
- Results first posted: 2024-08-20 (ClinicalTrials.gov record NCT03808376, source copy `cardio:ctgov-nct03808376-2024-08-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03808376, source copy `cardio:ctgov-nct03808376-2024-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03808376-2024-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
- Acronym: PROMISE
- Condition: Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Continuous Glucose Monitoring System
- Lead sponsor: Senseonics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Senseonics, Inc. (`cardio:org-senseonics-inc`)

## Provenance

Content hash: bc2dc90ad87e5f4556986379e4cab39432062e6b5c32b8b032399cf3095951a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
